J. Fennell George's most recent trade in Idexx Laboratories, Inc. was a trade of 11,345 Non-Qualified Stock Option (right-to-buy) done . Disclosure was reported to the exchange on Feb. 9, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Idexx Laboratories | George J. Fennell | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2026 | 11,345 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories | George J. Fennell | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 67.85 per share. | 09 Feb 2026 | 11,345 | 21,168 (0%) | 0% | 67.8 | 769,758 | Common Stock |
| Idexx Laboratories | George J. Fennell | Executive Vice President | Sale of securities on an exchange or to another person at price $ 649.26 per share. | 09 Feb 2026 | 2,809 | 9,863 (0%) | 0% | 649.3 | 1,823,771 | Common Stock |
| Idexx Laboratories | George J. Fennell | Executive Vice President | Sale of securities on an exchange or to another person at price $ 646.23 per share. | 09 Feb 2026 | 2,782 | 14,698 (0%) | 0% | 646.2 | 1,797,800 | Common Stock |
| Idexx Laboratories | George J. Fennell | Executive Vice President | Sale of securities on an exchange or to another person at price $ 645.25 per share. | 09 Feb 2026 | 2,161 | 17,480 (0%) | 0% | 645.3 | 1,394,388 | Common Stock |
| Idexx Laboratories | George J. Fennell | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 67.85 per share. | 09 Feb 2026 | 1,476 | 9,823 (0%) | 0% | 67.9 | 100,147 | Common Stock |
| Idexx Laboratories | George J. Fennell | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2026 | 1,476 | 0 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories | George J. Fennell | Executive Vice President | Sale of securities on an exchange or to another person at price $ 643.00 per share. | 09 Feb 2026 | 1,130 | 20,038 (0%) | 0% | 643.0 | 726,587 | Common Stock |
| Idexx Laboratories | George J. Fennell | Executive Vice President | Sale of securities on an exchange or to another person at price $ 647.21 per share. | 09 Feb 2026 | 1,060 | 13,638 (0%) | 0% | 647.2 | 686,039 | Common Stock |
| Idexx Laboratories | George J. Fennell | Executive Vice President | Sale of securities on an exchange or to another person at price $ 648.78 per share. | 09 Feb 2026 | 966 | 12,672 (0%) | 0% | 648.8 | 626,721 | Common Stock |
| Idexx Laboratories | George J. Fennell | Executive Vice President | Sale of securities on an exchange or to another person at price $ 644.02 per share. | 09 Feb 2026 | 397 | 19,641 (0%) | 0% | 644.0 | 255,674 | Common Stock |
| Idexx Laboratories | George J. Fennell | Executive Vice President | Sale of securities on an exchange or to another person at price $ 650.32 per share. | 09 Feb 2026 | 40 | 9,823 (0%) | 0% | 650.3 | 26,013 | Common Stock |
| Idexx Laboratories | George J. Fennell | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 3,415 | 3,415 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories | George J. Fennell | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 816 | 816 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | George J. Fennell | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 217 | 217 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories | George J. Fennell | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 140 | 8,480 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | George J. Fennell | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 140 | 417 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | George J. Fennell | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 444.53 per share. | 13 Feb 2025 | 133 | 8,347 (0%) | 0% | 444.5 | 59,122 | Common Stock |
| Idexx Laboratories | George J. Fennell | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 57 | 8,340 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | George J. Fennell | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 57 | 112 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | George J. Fennell | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 56 | 55 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | George J. Fennell | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 56 | 8,283 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | George J. Fennell | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 51 | 0 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | George J. Fennell | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 51 | 8,227 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | George J. Fennell | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 79.54 per share. | 07 Feb 2025 | 9,986 | 18,162 (0%) | 0% | 79.5 | 794,286 | Common Stock |
| Idexx Laboratories | George J. Fennell | Executive Vice President | Sale of securities on an exchange or to another person at price $ 462.53 per share. | 07 Feb 2025 | 9,986 | 8,176 (0%) | 0% | 462.5 | 4,618,862 | Common Stock |
| Idexx Laboratories | George J. Fennell | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2025 | 9,986 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories | George J. Fennell | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 79.54 per share. | 07 Feb 2025 | 1,256 | 8,176 (0%) | 0% | 79.5 | 99,902 | Common Stock |
| Idexx Laboratories | George J. Fennell | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2025 | 1,256 | 0 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories | George Fennell J. | SVP, Chief Revenue Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 2,408 | 2,408 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories | Fennell George J. | SVP, Chief Revenue Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 557 | 557 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Fennell J. George | SVP, Chief Revenue Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 178 | 178 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories | J. Fennell George | SVP, Chief Revenue Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 560.56 per share. | 14 Feb 2024 | 162 | 6,920 (0%) | 0% | 560.6 | 90,811 | Common Stock |
| Idexx Laboratories | Fennell J. George | SVP, Chief Revenue Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 108 | 0 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | George J. Fennell | SVP, Chief Revenue Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 108 | 6,820 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | George J. Fennell | SVP, Chief Revenue Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 97 | 0 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | J. George Fennell | SVP, Chief Revenue Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 97 | 6,917 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Fennell George J. | SVP, Chief Revenue Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 57 | 169 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Fennell J. George | SVP, Chief Revenue Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 57 | 7,082 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | J. George Fennell | SVP, Chief Revenue Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 56 | 7,025 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | J. Fennell George | SVP, Chief Revenue Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 56 | 111 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | George Fennell J. | SVP, Chief Revenue Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 52 | 6,969 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | George Fennell J. | SVP, Chief Revenue Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 52 | 51 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | George J. Fennell | SVP, Chief Revenue Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 62.00 per share. | 08 Feb 2024 | 8,198 | 14,910 (0%) | 0% | 62 | 508,276 | Common Stock |
| Idexx Laboratories | Fennell George J. | SVP, Chief Revenue Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 8,198 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories | George Fennell J. | SVP, Chief Revenue Officer | Sale of securities on an exchange or to another person at price $ 575.02 per share. | 08 Feb 2024 | 3,173 | 7,124 (0%) | 0% | 575.0 | 1,824,528 | Common Stock |
| Idexx Laboratories | Fennell J. George | SVP, Chief Revenue Officer | Sale of securities on an exchange or to another person at price $ 572.78 per share. | 08 Feb 2024 | 2,279 | 11,422 (0%) | 0% | 572.8 | 1,305,365 | Common Stock |
| Idexx Laboratories | J. George Fennell | SVP, Chief Revenue Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 62.00 per share. | 08 Feb 2024 | 1,612 | 6,712 (0%) | 0% | 62 | 99,944 | Common Stock |
| Idexx Laboratories | George J. Fennell | SVP, Chief Revenue Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 1,612 | 0 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories | Fennell George J. | SVP, Chief Revenue Officer | Sale of securities on an exchange or to another person at price $ 572.14 per share. | 08 Feb 2024 | 1,209 | 13,701 (0%) | 0% | 572.1 | 691,712 | Common Stock |
| Idexx Laboratories | George J. Fennell | SVP, Chief Revenue Officer | Sale of securities on an exchange or to another person at price $ 573.98 per share. | 08 Feb 2024 | 1,125 | 10,297 (0%) | 0% | 574.0 | 645,723 | Common Stock |
| Idexx Laboratories | George Fennell J. | SVP, Chief Revenue Officer | Sale of securities on an exchange or to another person at price $ 575.80 per share. | 08 Feb 2024 | 412 | 6,712 (0%) | 0% | 575.8 | 237,231 | Common Stock |